See more : Seco S.p.A. (IOT.MI) Income Statement Analysis – Financial Results
Complete financial analysis of Galectin Therapeutics Inc. (GALT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Galectin Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Odessa Minerals Limited (FNGGF) Income Statement Analysis – Financial Results
- Moura Dubeux Engenharia S.A. (MDNE3.SA) Income Statement Analysis – Financial Results
- Allied Motion Technologies Inc. (AMOT) Income Statement Analysis – Financial Results
- BELLUS Health Inc. (BLU.TO) Income Statement Analysis – Financial Results
- Systex Corporation (6214.TW) Income Statement Analysis – Financial Results
Galectin Therapeutics Inc. (GALT)
About Galectin Therapeutics Inc.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 33.00K | 32.00K | 41.00K | 36.00K | 35.00K | 0.00 | 1.00K | 7.00K | 7.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.33M | 6.46M | 7.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -33.00K | -32.00K | -41.00K | -36.00K | -35.00K | 0.00 | -1.00K | -7.00K | -7.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.33M | -6.46M | -7.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 32.13M | 31.74M | 23.82M | 17.98M | 7.47M | 6.47M | 11.72M | 15.33M | 13.11M | 8.43M | 5.69M | 4.53M | 3.55M | 1.07M | 1.11M | 1.77M | 2.05M | 3.02M | 3.04M | 3.04M | 1.95M | 1.48M | 893.46K | 100.00K |
| General & Administrative | 5.90M | 6.62M | 6.36M | 5.47M | 5.97M | 7.13M | 4.53M | 6.16M | 6.97M | 7.01M | 6.42M | 5.37M | 6.86M | 3.82M | 4.98M | 3.55M | 4.40M | 4.03M | 3.62M | 4.26M | 2.99M | 1.80M | 1.29M | 70.00K |
| Selling & Marketing | 44.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.94M | 6.62M | 6.36M | 5.47M | 5.97M | 7.13M | 4.53M | 6.16M | 6.97M | 7.01M | 6.42M | 5.37M | 6.86M | 3.82M | 4.98M | 3.55M | 4.40M | 4.03M | 3.62M | 4.26M | 2.99M | 1.80M | 1.29M | 70.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 38.07M | 38.35M | 30.18M | 23.44M | 13.44M | 13.60M | 16.25M | 21.48M | 20.08M | 15.43M | 12.10M | 9.90M | 10.41M | 4.88M | 6.09M | 5.33M | 6.46M | 7.05M | 6.66M | 7.30M | 4.94M | 3.29M | 2.18M | 170.00K |
| Cost & Expenses | 38.07M | 38.35M | 30.18M | 23.44M | 13.44M | 13.60M | 16.25M | 21.48M | 20.08M | 15.43M | 12.10M | 9.90M | 10.41M | 4.88M | 6.09M | 5.33M | 6.46M | 7.05M | 6.66M | 7.30M | 4.94M | 3.29M | 2.18M | 170.00K |
| Interest Income | 0.00 | 52.00K | 3.00K | 66.00K | 231.00K | 38.00K | 24.00K | 45.00K | 52.00K | 42.00K | 16.00K | 24.00K | 18.00K | 6.00K | 3.00K | 30.00K | 102.00K | 281.00K | 111.00K | 124.00K | 68.93K | 24.26K | 24.92K | 0.00 |
| Interest Expense | 2.56M | 1.03M | 489.00K | 87.00K | 87.00K | 336.00K | 12.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 350.00K | 1.85M | 0.00 | 0.00 | 3.88K | 415.42K | 0.00 | 0.00 |
| Depreciation & Amortization | 38.07M | 32.00K | 41.00K | 36.00K | 35.00K | 1.00K | 1.00K | 7.00K | 7.00K | 10.00K | 12.00K | 9.00K | 9.00K | 12.00K | 37.00K | 49.00K | 64.00K | 67.00K | 81.00K | 81.00K | 89.17K | 211.18K | 159.47K | -20.00K |
| EBITDA | -202.00K | -37.71M | -30.00M | -23.34M | -13.17M | -13.56M | -16.23M | -21.47M | -20.07M | -15.78M | -12.08M | -9.67M | -10.91M | -5.62M | -7.43M | -3.10M | -9.02M | -1.28M | -6.77M | -7.10M | -4.85M | -3.08M | -2.02M | -190.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -38.07M | -38.35M | -30.18M | -23.44M | -13.44M | -13.60M | -16.25M | -21.48M | -20.08M | -15.43M | -12.10M | -9.90M | -10.41M | -4.88M | -6.09M | -5.33M | -6.46M | -7.05M | -6.66M | -7.30M | -4.94M | -3.29M | -2.18M | -170.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.99M | -424.00K | -348.00K | -21.00K | 144.00K | -298.00K | 12.00K | 45.00K | 52.00K | -358.00K | 16.00K | 224.00K | -506.00K | -746.00K | -1.37M | 2.18M | -2.98M | 3.86M | 111.00K | 124.00K | 65.05K | -391.16K | 0.00 | -20.00K |
| Income Before Tax | -41.07M | -38.78M | -30.53M | -23.47M | -13.29M | -13.90M | -16.24M | -21.44M | -20.03M | -15.79M | -12.09M | -9.68M | -10.92M | -5.63M | -7.46M | -3.15M | -9.43M | -3.19M | -6.54M | -7.18M | -4.87M | -3.68M | 0.00 | -190.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 424.00K | 448.00K | 51.00K | 87.00K | -123.14K | 24.00K | 0.00 | 0.00 | -52.00K | 16.00K | 200.00K | 506.00K | 746.00K | 1.37M | -2.18M | 2.98M | -3.86M | 0.00 | 0.00 | 0.00 | 0.00 | 1.79M | 0.00 |
| Net Income | -41.07M | -39.20M | -30.98M | -23.52M | -13.38M | -13.90M | -16.24M | -21.44M | -20.03M | -15.79M | -12.09M | -9.68M | -10.92M | -5.63M | -7.46M | -3.15M | -9.43M | -3.19M | -6.54M | -7.18M | -4.87M | -3.68M | -3.97M | -190.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.74 | -0.66 | -0.53 | -0.41 | -0.26 | -0.35 | -0.46 | -0.73 | -0.83 | -0.72 | -0.72 | -0.64 | -0.91 | -0.60 | -0.93 | -0.40 | -1.45 | -0.67 | -1.44 | -1.67 | -1.37 | -1.35 | -1.75 | -0.09 |
| EPS Diluted | -0.74 | -0.66 | -0.53 | -0.41 | -0.26 | -0.35 | -0.46 | -0.73 | -0.83 | -0.72 | -0.72 | -0.64 | -0.91 | -0.60 | -0.93 | -0.40 | -1.45 | -0.67 | -1.44 | -1.67 | -1.37 | -1.35 | -1.75 | -0.09 |
| Weighted Avg Shares Out | 60.16M | 59.39M | 58.53M | 57.03M | 52.24M | 39.41M | 35.52M | 29.22M | 24.12M | 21.85M | 16.87M | 15.13M | 11.99M | 9.38M | 8.05M | 7.80M | 6.50M | 4.75M | 4.55M | 4.29M | 3.56M | 2.73M | 2.27M | 2.06M |
| Weighted Avg Shares Out (Dil) | 60.16M | 59.39M | 58.53M | 57.03M | 52.24M | 39.41M | 35.52M | 29.22M | 24.12M | 21.85M | 16.87M | 15.13M | 11.99M | 9.38M | 8.05M | 7.80M | 6.50M | 4.75M | 4.55M | 4.29M | 3.56M | 2.73M | 2.27M | 2.06M |
Galecto Biotech Collapse: Opportunity For Galectin Therapeutics
Galecto Biotech's stock has plummeted 75% due to increased rates of adverse events in its idiopathic pulmonary fibrosis (IPF) trial. Galecto's synthetic, small molecule approach to galectin-3 inhibition may be causing poor tolerability and negative clinical outcomes. Galectin Therapeutics' belapectin,...
Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023
NORCROSS, Ga., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held...
Galectin Therapeutics Inc. (GALT)'s Technical Outlook is Bright After Key Golden Cross
Galectin Therapeutics Inc. (GALT) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, GALT's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden...
Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023
NORCROSS, Ga., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held...
Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023
NORCROSS, Ga., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will participate in the 9th Edition of the Paris NASH meeting, where a select...
What Makes Galectin Therapeutics Inc. (GALT) a New Buy Stock
Galectin Therapeutics Inc. (GALT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update
NORCROSS, Ga., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2023. These...
7 Short-Interest Stocks to Target for Explosive Gains
Ranking among the most speculative practices in the equities arena, deliberately bidding up short-interest stocks may generate wildly robust gains. At the same time, higher risks for the intrepid market participant also signifies substantial risks.
Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit
NORCROSS, Ga., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be presenting at the 6th Obesity and NASH Drug Development Summit in Boston,...
Galectin Therapeutics to Present in Upcoming Conferences
NORCROSS, Ga., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be presenting at two upcoming conferences.
Source: https://incomestatements.info
Category: Stock Reports